(-0.64%) 5 074.75 points
(-0.25%) 38 583 points
(-1.14%) 17 463 points
(0.33%) $83.08
(-2.66%) $1.609
(-0.02%) $2 338.00
(0.33%) $27.44
(0.17%) $917.40
(-0.23%) $0.932
(-0.27%) $10.95
(-0.42%) $0.799
(-0.30%) $92.05
Live Chart Being Loaded With Signals
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally...
Stats | |
---|---|
Today's Volume | 4 133.00 |
Average Volume | 82 158.00 |
Market Cap | 4.04B |
EPS | €0 ( 2024-02-27 ) |
Next earnings date | ( €0 ) 2024-05-08 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | 24.62 |
ATR14 | €0.136 (0.17%) |
Volume Correlation
Laboratorios Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Laboratorios Correlation - Currency/Commodity
Laboratorios Financials
Annual | 2023 |
Revenue: | €829.51M |
Gross Profit: | €492.29M (59.35 %) |
EPS: | €3.29 |
Q4 | 2023 |
Revenue: | €234.64M |
Gross Profit: | €138.57M (59.06 %) |
EPS: | €0 |
Q3 | 2023 |
Revenue: | €214.03M |
Gross Profit: | €136.26M (63.66 %) |
EPS: | €0.980 |
Q2 | 2023 |
Revenue: | €179.22M |
Gross Profit: | €91.44M (51.02 %) |
EPS: | €0.360 |
Financial Reports:
No articles found.
Laboratorios
Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are licensed from other laboratories. Its principal products include Hibor, a low-molecular-weight heparin to prevent and treat venous thromboembolic disease; Enoxaparin biosimilar Becat, a low-molecular-weight heparin; Neparvis to treat symptomatic chronic heart failure with reduced ejection in adult patients; Absorcol, Vytorin, and Orvatez to diet in patients with hypercholesterolemia; Hirobriz Breezhaler and Ulunar Breezhaler that are long-acting bronchodilators for the maintenance treatment of chronic obstructive pulmonary diseases; Volutsa for treatment of moderate to severe storage systems symptoms and voiding symptoms associated with benign prostatic hyperplasia in men who are not responding adequately to monotherapy treatment; and Medikinet and Medicebrán to treat attention deficit hyperactivity disorder in children and teenagers. The company also markets various hospital products for imaging diagnosis, such as Iomeron and Iopamiro for computed tomography and intervention; Multihance and Prohance for magnetic resonance imaging; Sonovue for ultrasounds; and EmpowerCTA+, EmpowerMR, and CT Exprès that are contrast injection systems and compatible disposable material. It provides non-prescription pharmaceutical products; and contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, hard capsules, and sachets. The company serves wholesalers, doctors, nursing staff, pharmacists, and patients. It has a collaboration with Moderna, Inc. for manufacturing mRNA COVID-19 vaccine candidate. The company was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators